Effect of transfection time on the survival of epigastric skin flaps pretreated with adenovirus encoding the VEGF gene

Annals of Plastic Surgery

Volumn 49, Issue 2, 2002, Pages 161-169

  Gurunluoglu, Raffi ^a   Ozer, Kagan ^a   Skugor, Blazenka ^a   Lubiatowski, Przemyslaw ^a,b   Carnevale, Kevin ^a   Siemionow, Maria ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b The Kosciuszko Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; VASCULOTROPIN; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; PHOTOPROTEIN; SIGNAL PEPTIDE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DONOR SITE; DRUG EFFECT; GENE THERAPY; GENETIC TRANSFECTION; GRAFT SURVIVAL; INFLAMMATION; MALE; NONHUMAN; PLASTIC SURGERY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKIN FLAP; SKIN NECROSIS; SURGICAL TECHNIQUE; SUTURING METHOD; ABDOMINAL WALL; ADENOVIRUS; ANGIOGENESIS; ANIMAL; ANIMAL MODEL; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING ORGAN SYSTEMS; EPIGASTRIC ARTERY; EVALUATION; FLUORESCENCE MICROSCOPY; GENE VECTOR; GENETICS; METHODOLOGY; NECROSIS; PATHOLOGY; SPRAGUE DAWLEY RAT; TIME; VASCULARIZATION;

ABDOMINAL WALL; ADENOVIRIDAE; ANIMALS; ENDOTHELIAL GROWTH FACTORS; EPIGASTRIC ARTERIES; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; INDICATORS AND REAGENTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUMINESCENT PROTEINS; LYMPHOKINES; MALE; MICROSCOPY, FLUORESCENCE; MODELS, ANIMAL; NECROSIS; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; SURGICAL FLAPS; TIME FACTORS; TISSUE SURVIVAL; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036022299     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000637-200208000-00009     Document Type: Article

References (34)

1. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
2. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
3. Mechanisms of angiogenesis and arteriogenesis
4. Therapeutic angiogenesis
5. Effect of vascular endothelial growth factor (VEGF) on survival of random extension of axial pattern skin flaps in the rat
6. Effects of VEGF administration following ischemia on survival of the gracilis muscle flap in the rat
7. The effects of VEGF on survival of a random flap in the rat: Examination of various routes of administration
8. Improved perfusion after subcritical ischemia in muscle flaps treated with vascular endothelial growth factor
9. Microangiographic assessment of collateral vessel formation following direct gene transfer of vascular endothelial growth factor in rats
10. Effect of time on the viability of ischemic skin flaps treated with vascular endothelial growth factor (VEGF) cDNA
11. Locally administered vascular endothelial growth factor cDNA increases survival of ischemic experimental skin flaps
12. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion
13. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
14. Vascular endothelial growth factor (165) gene transfer augments circulating endothelial progenitor cells in human subjects
15. Gene therapy for tissue repair approaches and prospects
16. Assessing the role of gene therapy in the treatment of vascular disease
17. Cardiovascular gene therapy
18. Enhancement of epigastric flap survival by adenovirus-mediated VEGF gene therapy
19. Enhancement of muscle flap hemodynamics by angiopoietin-1
20. Modification in flap design of the epigastric artery flap in rats-a new experimental flap model
21. Plastic surgical perspectives on vascular endothelial growth factor as gene therapy for angiogenesis
22. Adeno-associated virus-mediated vascular endothelial growth factor gene transfer into cardiac myocytes
23. Efficient expression of vascular endothelial growth factor gene in vitro and in vivo using an adeno-associated virus vector
24. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion
25. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability
26. Improvement of skin flap perfusion by subdermal injection of recombinant human basic fibroblast growth factor
27. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia
28. Six-month assessment of phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF 121
29. Virus treatment questioned after gene therapy death
30. Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121
31. Adenovirus-mediated gene transfer into normal arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia
32. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors
33. Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors